Factor 8 Hemlibra denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Hemlibra on Medical-Necessity Grounds — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) is FDA-approved for prophylaxis in patients with hemophilia A. Aetna's medical-necessity denials for Hemlibra typically arise when the plan determines that the clinical documentation submitted does not satisfy one or more of its coverage criteria — most commonly related to inhibitor status, bleeding frequency, prior prophylaxis history, or specialist involvement. The denial does not mean Hemlibra is wrong for your patient; it means the documentation package was incomplete or did not map directly to Aetna's written criteria.

## Why This Denial Is Appealable

Medical-necessity determinations must be based on the plan's published criteria and applied consistently with current clinical evidence. If the clinical record supports the criteria but the documentation was not presented in the format the reviewer needed, an appeal with a structured criteria-mapping letter frequently succeeds. External reviewers must apply objective clinical standards, not administrative convenience.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review; 180 days from denial to file internally.
• ACA §2719 (fully-insured plans): Independent external review after internal exhaustion; generally within four months of the final internal denial.
• Expedited review: If the standard timeline would seriously jeopardize the patient's health or ability to regain maximum function, request expedited processing — typically 72-hour resolution at both stages.

## Concrete Appeal Steps and Timeline

1. Obtain the full denial notice and identify every criterion Aetna states was not met. 2. Request Aetna's complete published coverage policy for Hemlibra. 3. Audit the original prior-authorization submission against each criterion. 4. Assemble the documentation gaps identified in the audit. 5. File the internal appeal with a structured criteria-mapping letter and supporting records. 6. If denied internally, escalate to independent external review within four months.

## Documentation to Gather

• Hemophilia A diagnosis: Specialist-confirmed diagnosis with inhibitor status (present or absent) clearly documented.
• Bleeding history: Annualized bleed rate from the chart; joint damage assessments; hospitalization records for bleeding episodes.
• Prior-treatment history: Every prior prophylaxis or on-demand regimen — product name, dates, dosing, and outcome — particularly any inhibitor-related complications.
• Specialist involvement: Documentation that a hematologist or comprehensive hemophilia treatment center is managing care.
• Prescriber medical-necessity letter: The hematologist should address each of Aetna's coverage criteria point by point, citing the specific chart finding that satisfies each one. Reference the relevant guideline organization (e.g., the applicable ASH or WFH guideline) without asserting specific numeric thresholds.

## Criteria-Mapping Structure

Print Aetna's coverage policy criteria verbatim in a table. In the adjacent column, cite the chart document, date, and exact finding that satisfies each criterion. For any criterion the plan says was unmet, explain in clinical detail why the record in fact satisfies it, or provide the supplemental documentation that fills the gap. This structure is the most effective format for medical-necessity appeals in hemophilia A, where coverage policies are typically detailed and specific.